| Literature DB >> 35078667 |
Suvaporn Anugulruengkitt1, Piyada Angsuwatcharakon2, Thanyawee Puthanakit3, Pornumpa Bunjoungmanee4, Patchareeyawan Srimuan5, Ekkasit Kowitdamrong6, Panadda Sawangsinth5, Jiratchaya Sophonphan7, Terapong Tantawichien8, Auchara Tangsathapornpong4.
Abstract
Thailand has implemented single-dose mumps-containing vaccines since 1997 and two doses since 2010. This study aimed to describe the seroprevalence of mumps among children who received one- or two-dose mumps vaccines. A cross-sectional study of 145 children (aged 3-9 years) and 422 adolescents (10-18 years) was conducted. Mumps IgG seropositivity was defined as ≥ 22 RU/mL by EUROIMMUN ELISA method. The mumps seroprevalence was higher in children (82.1%, 95% CI 74.8-87.9) compared to adolescents (41.7%, 95% CI 37.0-46.6) who had received at least one dose of the mumps vaccine. Among those receiving 2 doses of mumps vaccine at ≥ 5 years after their last mumps vaccination, only 51.3% had maintained IgG ≥ 22 RU/ml. There was a reverse correlation between mumps IgG titer and the time interval from the second dose of mumps vaccine (R = -0.44, p < 0.001). A booster dose of MMR vaccine in young adults may be needed.Entities:
Keywords: Adolescents; Children; Mumps; Seroprevalence
Mesh：
Substances：
Year: 2022 PMID： 35078667 DOI： 10.1016/j.vaccine.2022.01.019
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641